CD8A and breast carcinoma: In the field of breast cancer, a few studies have used m‐IHC to detect differences in components of the TIME between different molecular types, the relationship between components of the TIME and the efficacy of neoadjuvant therapy, and the relationship between PD‐1+ CD8+ double‐positive cells and prognosis.10, 11, 12